INO (inovio.com) Enterprise Value-to-Revenue Ratio

Official company branding of Inovio (INO)

Geopolitical tensions and bio-threats are driving demand for vaccines, although sanctions complicate logistics. Strategic partnerships of Inovio Pharmaceuticals (INO) are accelerating DNA drug trials, while FDA approval strengthens investor confidence. The EV/Sales multiple visualizes the actual value of the business excluding debt, with 930733.33 representing the latest level, helping to identify asset overvaluation in a timely manner.

INO Inovio: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

INO (Inovio): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:Inovio Pharmaceuticals INO
Product sample of inovio.com

Optimizing DNA vaccine logistics and ensuring seamless air transport minimize operational risks for Inovio Pharmaceuticals (INO). The EV/Sales metric relates the total enterprise value, including debt minus cash, to annual revenue. Investors utilize this ratio to assess the market premium paid per unit of revenue. An increase in this indicator signals a capital inflow but raises the probability of a correction. This EV to Sales chart reflects the dynamics of these expectations.